A PUBLISHER’S VIEW ON RWE STUDIES AND ARTICLES

JOANNE WALKER
HEAD OF PUBLISHING SOLUTIONS

7TH EMWA SYMPOSIUM
9 MAY 2019
REAL-WORLD EVIDENCE: A CENTRAL ROLE FOR MEDICAL COMMUNICATORS
A platform for informed decisions on which treatment, for whom and when

- MEDLINE-indexed
- Impact Factor: 1.906
- ~6,000 views/month
- ~75% acceptance rate

www.evidencebaseonline.com
Consider your audience = journal choice?
Consider your research = methodology publication?

**RESEARCH ARTICLE**

Treatement registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

David D. Fossa1, David G. Llanes2, Lawrence Karch3, David Quinter4, David H. Miller3, Neal Shah3, James T. Symmans5, Bruce Spencer6, David Flower7, Elaine K. Weng7

*Purpose: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL) clinical outcome rates in patients with castration-resistant prostate cancer (CRPC). Patients & methods: Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET) is an observational study designed to systematically collect real-world treatment data (treatment patterns and outcomes) in patients with CRPC. The registry is currently active in the US and in several European countries. Data are collected from various sources including electronic medical records, patient-reported outcomes, and healthcare professionals. Data are de-identified and analyzed using appropriate statistical methods to provide insights into treatment patterns and clinical outcomes.*

**Journal of Comparative Effectiveness Research**

PHENOMA: using real-world data to analyze treatment patterns and brinulinib effectiveness in hematological malignancies

James L. Swerdlow1, Natalia Krams2, Hamed Bajani3, Robert H. Storb Jr.4, Frank W. Makrigiannis5, Daniel L. Culpepper6, Arnie D. Tannenbaum7, Vassilis Arapoglou8

*Purpose: To evaluate the effectiveness of brinulinib, a novel oral inhibitor of the fibroblast growth factor receptor (FGFR) family, in real-world hematologic malignancies. The study is an observational, non-interventional registry involving patients with hematological malignancies treated with brinulinib. Data are collected from various sources, including electronic medical records, and are analyzed using appropriate statistical methods to assess treatment patterns and outcomes.*

**Clinical Trial Protocol**

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Carolina Castellano1, David E. Neidhart2, Gordon Cawley3, Jorge A. Godoy4, Jim D. Shaw5, Robert M. Hoss6, Haefi Bertsch7, Nuovo Priolo8, David Z. Cawley9, John S. Dishman10, benches & Swanson11, Michael A. Thompson12, Gregory C. Dunsford13, John Marks, Stuart14, Varun Haripriya15

*Purpose: To evaluate the real-world effectiveness of treatments for multiple myeloma. INSIGHT MM is a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Data are collected from various sources, including electronic medical records, and are analyzed using appropriate statistical methods to assess treatment patterns and outcomes.*

**Clinical Epidemiology**

Missing data and multiple imputation in clinical epidemiological research

Afsana B. Pedersen1, Eleni M. Misselen1, Cindrese Grootenl4, Natalia N. Kroeksten1, The Myr Ptole1, Lars Pedersem1, Nadia P. Pedersen1, Lars Pedersen1

*Purpose: To evaluate the impact of missing data on the accuracy of epidemiological research. The study assesses the effectiveness of multiple imputation techniques in handling missing data in epidemiological studies. Data are collected from various sources, including electronic medical records, and are analyzed using appropriate statistical methods to assess the impact of missing data on the accuracy of epidemiological research.*
Consider your research = digital enhancements needed?
Consider your research = digital enhancements needed?
Consider your reach = open access, social media etc?
Thank you